title: [Sustained dynamic release characteristics of fibrin glue enwrapping cisplatin].
abstract: OBJECTIVE
  To summarize the sustained dynamic release characteristics of fibrin glue enwrapping cisplatin.
  
  
  METHODS
  In this in vivo study, 20 patients received fibrin glue enwrapping cisplatin placed into the abdominal cavity while another 20 patients received cisplatin as the control group. Their peripheral blood and urine samples were collected at a regular interval to determine the concentrations and the pharmacokinetic parameters of cisplatin.
  
  
  RESULTS
  The peak peripheral blood concentration of cisplatin in the study group was significantly lower than that in the control group [(192.2 ± 33.5) vs (1077.6 ± 176.6) µg/L, P < 0.01]. And the peak urine concentration of cisplatin was significantly lower in the study group than that in the control group [(18.6 ± 8.7) vs (55.8 ± 12.7) µg/L, P < 0.01]. The elimination half-life of cisplatin was 23.32 h and 13.93 h respectively in the study and control groups. The elimination half-life and the area under the curve in peripheral blood and urine samples of the study group were significantly longer than those of the control group (P < 0.01).
  
  
  CONCLUSIONS
  The fibrin glue enwrapping cisplatin has the excellent in vivo characteristics of sustained dynamic release. Thus it may prolong the retention of cisplatin in abdominal cavity and lower its concentration in peripheral blood.
authors.affiliation: Lishui Municipal People's Hospital, Lishui 323000, China.
authors.forename: Xiang-Dong
authors.initials: XD
authors.lastname: Xu
authors.forename: Xiang-Hong
authors.initials: XH
authors.lastname: Lu
authors.forename: Yong
authors.initials: Y
authors.lastname: Shi
authors.forename: Guan-Xiong
authors.initials: GX
authors.lastname: Ye
authors.forename: Xi-Yuan
authors.initials: XY
authors.lastname: Zhu
mesh_terms: D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D015718:Fibrin Tissue Adhesive / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy
chemical_list: D015718:Fibrin Tissue Adhesive; D002945:Cisplatin